title: Yeast mediates lactic acidosis suppression after antibiotic cocktail treatment in short small bowel?
abstract: During acidotic periods in a girl with a short small bowel, very high D-lactic acid concentrations were measured in blood and urine; the patient's characteristic faecal flora contained mainly lactobacilli, and during antibiotic cocktail treatment also many yeasts. In this case report we sought to understand the beneficial effect of the antibiotic cocktail. Microbiological analysis was performed in faecal samples. Total lactic acid in serum and urine was studied using capillary gas chromatography-mass spectrometry, and D- and L-lactic acid in serum and urine by enzymatic assay. The results were coupled to patient's condition. Antibiotic cocktail therapy reduced the acidosis-associated symptoms, faecal lactobacilli and D-lactic acid production, but simultaneously the antibiotic therapy strongly increased the percentage of yeast in the faecal flora. Four to six weeks after each course of treatment the percentage of yeast decreased, whereas the percentage of intestinal lactobacilli increased; D-lactic acid also simultaneously increased in blood and urine. The patient felt well and showed a high percentage of intestinal yeast, but she often suffered from acidosis owing to a high percentage of lactobacilli. The yeast was identified as the pathogenic Candida glabrata. From the mentioned data together with data from the literature it was concluded that during several weeks the selected pathogenic yeast, C. glabrata, acted as a microbiological and metabolic buffer. Shortly after the course of antibiotic treatment this intestinal yeast strongly competed with the intestinal lactobacilli and thus prevented renewed rapid growth, massive D-lactic acid production from glucose and consequently also D-lactic acid-associated acidosis. The emergence of this yeast led us to consider probiotic lactobacilli or yeast for therapeutic use. The lack of knowledge regarding bile acid-deconjugating activity in both lactobacilli and probiotic yeast means that a final recommendation is not yet possible.
authors.affiliation: Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. G.Bongaerts@mmb.umcn.nl
authors.forename: Ger
authors.initials: G
authors.lastname: Bongaerts
authors.forename: René
authors.initials: R
authors.lastname: Severijnen
authors.forename: Daniela
authors.initials: D
authors.lastname: Skladal
authors.forename: Jan
authors.initials: J
authors.lastname: Bakkeren
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Sperl
mesh_terms: D000140:Acidosis, Lactic / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology / Q000652:urine; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002648:Child; D003091:Colistin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005243:Feces / Q000382:microbiology; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007778:Lactobacillus / Q000187:drug effects; D008795:Metronidazole / Q000627:therapeutic use; D012778:Short Bowel Syndrome / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000652:urine; D014640:Vancomycin / Q000627:therapeutic use; D015003:Yeasts / Q000187:drug effects* / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D005839:Gentamicins; D008795:Metronidazole; D014640:Vancomycin; D003091:Colistin